Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib

Leukemia

Volumn 31, Issue 5, 2017, Pages 1136-1144

  Shide, K ^a   Kameda, T ^a   Yamaji, T ^a   Sekine, M ^a   Inada, N ^a   Kamiunten, A ^a   Akizuki, K ^a   Nakamura, K ^a   Hidaka, T ^a   Kubuki, Y ^a   Shimoda, H ^a   Kitanaka, A ^a   Honda, A ^b   Sawaguchi, A ^a   Abe, H ^a   Miike, T ^a   Iwakiri, H ^a   Tahara, Y ^a   Sueta, M ^a   Hasuike, S ^a   Yamamoto, S ^a   Nagata, K ^a   Shimoda, K ^a   more..

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE; RUXOLITINIB; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

293T CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL MATURATION; CMK11-5 CELL LINE; ENZYME ACTIVITY; ERYTHROLEUKEMIA CELL; F-36P-MPL CELL LINE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE COUNT; MEGAKARYOBLAST; MEGAKARYOCYTE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL SELF-RENEWAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TRANSGENIC MOUSE; TRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SELF-RENEWAL; CHEMICALLY INDUCED; GENETICS; HEK293 CELL LINE; METABOLISM; MYELOPROLIFERATIVE DISORDERS; THROMBOCYTHEMIA, ESSENTIAL;

ANIMALS; CALRETICULIN; CELL SELF RENEWAL; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASES; MICE; MICE, TRANSGENIC; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; STAT5 TRANSCRIPTION FACTOR; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84997787492     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.308     Document Type: Article

References (39)

1. Swerdlow SH (ed). Myeloproliferative neoplasms. In: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008, pp 40-50.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
3. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
6. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123: e123-e133.
7. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
8. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
9. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
10. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013; 369: 2379-2390.
11. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
12. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I, Marty C et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2016; 127: 1325-1335.
13. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016; 127: 1307-1316.
14. Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2016; 127: 1317-1324.
15. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552-1555.
16. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-1551.
17. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062-1069.
18. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
19. Numata A, Shimoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K et al. Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway. J Biol Chem 2005; 280: 12621-12629.
20. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998; 91: 2272-2282.
21. Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 2005; 29: 761-769.
22. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22: 87-95.
23. Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells 1997; 15(Suppl 1): 105-111, discussion 112.
24. Nagano T, Ohga S, Kishimoto Y, Kimura T, Yasunaga K, Adachi M et al. Ultrastructural analysis of platelet-like particles from a human megakaryocytic leukemia cell line (CMK 11-5). Int J Hematol 1992; 56: 67-78.
25. Chiba S, Takaku F, Tange T, Shibuya K, Misawa C, Sasaki K et al. Establishment and erythroid differentiation of a cytokine-dependent human leukemic cell line F-36: a parental line requiring granulocyte-macrophage colony-stimulating factor or interleukin-3, and a subline requiring erythropoietin. Blood 1991; 78: 2261-2268.
26. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol 2014; 167: 418-420.
27. Boggs DR. The total marrow mass of the mouse: a simplified method of measurement. Am J Hematol 1984; 16: 277-286.
28. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
29. Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 2015; 125: 304-315.
30. Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012; 119: 1363-1369.
31. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446-2452.
32. Kaushansky K. Mpl and the hematopoietic stem cell. Leukemia 2002; 16: 738-739.
33. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92: 4-10.
34. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
35. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798.
36. Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A et al. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. Br J Haematol 2016; 173: 938-940.
37. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis-an update of its clinical effects. Clin Lymph Myeloma Leuk 2013; 13: 638-645.
38. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372: 426-435.
39. Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A et al. Mutant calreticulin requires both its mutant c-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov 2016; 6: 368-381.